Your browser doesn't support javascript.
Longitudinal evaluation of azithromycin and cytokine concentrations in amniotic fluid following one-time oral dosing in pregnancy.
Boelig, Rupsa C; Lam, Edwin; Rochani, Ankit; Kaushal, Gagan; Roman, Amanda; Kraft, Walter K.
  • Boelig RC; Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Lam E; Department of Clinical Pharmacology and Experimental Therapeutics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Rochani A; Department of Clinical Pharmacology and Experimental Therapeutics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Kaushal G; Clinical Pharmacokinetics Research Unit, Pharmacy Department, National Institutes of Health, Bethesda, Maryland, USA.
  • Roman A; College of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Kraft WK; College of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Clin Transl Sci ; 14(6): 2431-2439, 2021 11.
Article in English | MEDLINE | ID: covidwho-1526358
ABSTRACT
To utilize noninvasive collection of amniotic fluid in the setting of preterm premature rupture of membranes (PPROMs) to report the time concentration profile of azithromycin in amniotic fluid over 7 days from a single dose, and evaluate the correlation between azithromycin concentration and inflammatory markers in amniotic fluid. Prospective cohort study of five pregnant patients admitted with PPROMs and treated with a single 1 g oral azithromycin dose. Amniotic fluid was collected from pads and used to quantify azithromycin concentration as well as TNFa, IL-1a, IL-1b, IL-6, IL-8, and IL-10 concentrations. Primary outcome was time/concentration profile of azithromycin in amniotic fluid. Secondary outcome included correlation between azithromycin concentration and cytokine concentrations. Five patients were enrolled. Mean gestational age on admission with PPROM was 27.5 ± 2.3 weeks with a median latency of 7 days (interquartile range [IQR] = 4-13). A median of two samples/day (IQR = 1-3) were collected per participant. Azithromycin was quantified in duplicate; intra-assay coefficient of variation was 17%. Azithromycin concentration was less than 60 ng/ml after day 3. Azithromycin concentration was positively correlated with IL-8 (r = 0.38, p = 0.03), IL1a (r = 0.39, p = 0.03), and IL-1b (r = 0.36, p = 0.04) in amniotic fluid. Azithromycin is detectable in amniotic fluid over 7 days from a single 1 g maternal dose, however, it is not sustained over the range of minimum inhibitory concentration for common genitourinary flora. Based on correlation with specific cytokines, azithromycin penetration in amniotic fluid may relate to maternal monocyte concentration in amniotic fluid in the setting of PPROM.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cytokines / Azithromycin / Amniotic Fluid Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Female / Humans / Pregnancy Language: English Journal: Clin Transl Sci Year: 2021 Document Type: Article Affiliation country: Cts.13111

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cytokines / Azithromycin / Amniotic Fluid Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Adult / Female / Humans / Pregnancy Language: English Journal: Clin Transl Sci Year: 2021 Document Type: Article Affiliation country: Cts.13111